Compare Sana Biotechnology Inc (SANA) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vital Farms Inc — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Vital Farms Inc trades at $9.33 (market cap $405.27M). The key difference: Sana Biotechnology Inc is far larger — about 2.1× Vital Farms Inc's market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 1,810,837). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Vital Farms Inc for 14 Days on average.
| SANA | VITL | |
|---|---|---|
Market Cap | $836.71M | $405.27M |
Volume | 4,507,444 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $5.92 | $43.40 |
52-Week Low | $2.68 | $8.28 |
Typical Hold Time | 23 Days | 14 Days |
Enterprise Value | $749.96M | $492.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Vital Farms (VITL) trades at $9.435, up 2.11% today, amid a challenging period marked by volatile earnings and a bearish technical signal. The stock shows weak profitability with a net income margin of 0.02% in 2026, though valuation ratios like P/S of 0.55 appear attractive. Recent news highlights strategic review for a potential sale, with price targets ranging from $10 to $20. Cash flow remains negative, driven by heavy investing activities, while institutional interest persists with new acquisitions.
The outlook is mixed: analyst consensus is bullish with a $13.11 target, but near-term risks include pricing pressure in the egg market and earnings volatility. Recovery hinges on stabilizing supply costs and executing strategic options. Investors should weigh low valuation against operational challenges and industry headwinds for potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
